

EXHIBIT 2

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

IN RE PHARMACEUTICAL INDUSTRY
AVERAGE WHOLESale PRICE LITIGATION

MDL No. 1456

THIS DOCUMENT RELATES TO:

CIVIL ACTION: 01-CV-12257-PBS

ALL ACTIONS

Judge Patti B. Saris

**COURT'S EXHIBIT LIST
PLAINTIFFS' EXHIBITS IN EVIDENCE**

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
14	11/14/06		X	Memorandum from Market Strategy & Contract Operations and the Zoladex Marketing Team	
15	1/19/07		X	E-mail from Margaret Hammons to George Gerhart III	
17	1/19/07		X	E-mail exchange re: Drug Topics Red Book and PDR.	
19	1/19/07		X	Internal memorandum from Keith Patterson to Chris Iacono	
29	12/18/06		X	Letter from Paula Jordon.	
33	12/4/06		X	E-mail from Barbara Villani to Joseph Mansfield	
38	12/18/06		X	Letter from Chris Bowman to Members of the "Maricopa Urology Lithotripsy Inc." Group	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
41	12/18/06		X	E-mail from Barnabas Desta to David Meddis	
43	1/19/07		X	AstraZeneca Pharmaceuticals Agreement	
44	12/18/06		X	Internal Memorandum to Chris Iacono from Keith Patterson	
45	12/18/06		X	Internal Memorandum to Chris Iacono from Keith Patterson	
46	12/18/06		X	September 10, 1996 letter from M. Painter to M. Reisenauer	
47	1/19/07		X	Letter from M. Painter to T. Arenson	
48	12/18/06		X	Fax from C. Ware to M. Reisenauer	
57	11/16/06		X	Letter to Mark J. Harberberger from William C. Lucas	
67	12/18/06		X	Email from Nancy Jones to Holle Terkhorn re: Annual Buy Group Zoladex Contract Template	
78	12/18/06		X	Internal Memorandum from Mark Reisenauer to Keith Patterson and Steve Strand re: Zoladex Price Increase Recommendation	
98	12/18/06		X	Fax to Keith Patterson & Mark Reisenaur from Carol Ware re:	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				Colorado Medicare Part B	
118	12/18/06		X	Memorandum to Chris Iacono from Keith Patterson re: Zoladex Pricing Strategy	
119	12/18/06		X	Memorandum to William Simpson from Keith Patterson re: Zoladex Pricing	
125	12/18/06		X	Letter to Ms. Rita Crook, North Carolina Medicare Part B from Sean Coakley	
131	12/18/06		X	Medicare Review	
133	11/14/06		X	Internal Memorandum from Keith Patterson to Chris Iacono re: Zoladex Pricing	
142	12/18/06		X	Proposed Zoladex Contracting Strategy	
143	12/18/06		X	Zoladex 3-Month 10.8mg Depot Pricing Proposal	
145	12/18/06		X	Internal Memorandum to Keith Patterson from Chris Iacono re: Zoladex	
146	11/28/06		X	Internal Memorandum to C. J.	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				Iacono from M. L. Rickards re: 1998 Pricing Recommendations – Prostate Cancer Portfolio	
153	12/18/06		X	Call Notes	
167	12/18/06		X	Email from Jill Krating to Erik Schultz re: NEW PDF of Pricing News	
179	11/13/06		X tabs 1 – 4	Composite exhibit of various letters to publishers from BMS	
180	11/13/06		X	Price Increase/Decrease Notification Process	
183	11/13/06		X tab 5 only	Letters from Kaszuba to publishers changing markup factor	
187	12/18/06		X	Email from Greg Fersko to various attaching PowerPoint slides	
188	11/13/06		X	Pricing procedures	
189	12/18/06		X	Email from Leigh Anne Leas to various attaching PowerPoint slides	
190	11/13/06		X	Composite exhibit of three Internal Price Lists	
191	11/13/06		X	Pocket Reference Price List	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
192	12/18/06		X	Composite exhibit of issues of OTN <i>The Network News</i>	
193	12/6/06		X	OTN AWP Price Report	
195	12/18/06		X	AWP (Ain't What's Paid)	
196	12/8/06		X	Understanding AWP's	
197	12/18/06		X	Reimbursement in Office Based Oncology	
199	12/18/06		X	Memo from Barbara Nathan to John Akscin, among others	
201	12/6/06		X	Memorandum from Ron Miller to Mark Durand re: Oncology Policy Issues	
202	12/18/06		X	Email from Barnard to various	
203	12/18/06		X	Taxol contract sales	
204	12/18/06		X	Oncology Customer Contract Proposal and Consorta contract pricing	
205	12/18/06		X	Oncology Customer Contract Proposal and Owen contract pricing	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
206	11/14/06		X	Email from Barnard with Premier contract pricing	
207	11/14/06 def		X	Email from Barnard with MHA contract pricing	
208	12/18/06		X	Etopophos Launch Plan	
209	11/13/06		X tab 6,7 only	Various Kaszuba letters and memos	
210	11/13/06		X tab 8	Albuterol pricing	
211	11/13/06		X tab 9	Trimox pricing	
213	11/14/06		X	Blenoxane contract sales	
215	11/14/06		X	Christof Marre, "Taxol Generic Strategy Learnings from the U.S.	
219	12/6/06		X	OTN Cost Differential Report	
220	12/18/06		X	BMS Overview: Values Unique to POHMS	
221	12/18/06		X	Taxane Economics: Effect of Dose and Schedule	
222	12/6/06		X	Practice Efficiencies & Quality Care Workshop – Of Special Interest To: Physicians, Nurses, Office	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				Managers, Billers	
223	11/28/06		X	Email from Janine Suscewicz transmitting Jan 26 Memo and accompanying BMS interrogatory responses to which the documents were attached	
224	12/18/06		X	Composite exhibit of Soule spread marketing documents	
225	12/18/06		X	Composite exhibit of Davidson spread marketing docs	
226	12/6/06		X	Greg Bell/Charles River Associates email attaching docs including Paraplatin Deconversion PowerPoint	
228	12/8/06		X	Marsha Peterson email and business plan	
229	12/18/06		X	Composite exhibit of call notes	
232	12/18/06		X	Akscin email attaching "Law & Order: OBO" PowerPoint	
234	11/14/06		X	OBO Opportunities	
236	12/18/06		X	Email from Catherine Piech re: Amgen AWP Spread Change to 25%	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
237	12/18/06		X	Price Change Notifications	
238	12/18/06		X	Urgent – Price Change Information	
242	12/18/06		X	1998 Reimbursement Update and Challenges	
244	12/18/06		X	Memorandum from John Dempsey to Gary Reedy and Bill Pearson re: Price Increase	
248	12/18/06		X	Charts regarding Procrit	
249	12/18/06		X	Remicade cA2 Marketing Plan U.S. Crohn's Indication Launch	
250	12/18/06		X	Letter Ron Krawczyk to Kathy Gutegesell at FirstData Bank	
252	11/14/06		X	Remicade Office Based Infusion Guide	
254	11/14/06		X	PowerPoint titled "Local Payer Information" Laura Glassco-National Account Manager, Ken Wegner-Regional Account Manager; Centocor, Inc.	
255	1/19/07		X	Pharmaceutical Sales Agreement with Caremark	
256	1/19/07		X	Pharmaceutical Sales Agreement with Stadtlanders	
259	11/16/06		X	Email from Cathleen Dooley	
260	12/18/06		X	Memorandum from Centocor's	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				Michael Ziskind to Jason Rubin	
261	11/14/06		X	Letter to C. Klaye Riley from Valerie	
262	11/16/06		X	Memorandum from C. Dooley to G. Reedy	
263	11/16/06		X	Memorandum from Gary Reedy to Carol Webb	
268	12/18/06		X	Memorandum to Minneapolis District from John Hess	
269	12/18/06		X	Bulletin No. 07 to Orlando District from David Rybak re: 1 st Quarter Successes and Team Experiences	
270	12/18/06		X	From Mycrocytic Cells to Macrocytic Sales – Regional Training Workshop Materials held in Houston, Texas	
272	12/18/06		X	E-mail from Laura Glassco to Tom Weiss, et al. re Dr. Kassan with attached PowerPoint titled "Local Payer Information" Laura Glassco- National Account Manager, Ken Wegner-Regional Account Manager; Centocor, Inc.	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
281	12/18/06		X	E-mail from Seth Fischer to Joseph Scodari, et al. re: "AWP Reporting issue: an overview"	
285	11/14/06		X	Document titled "Cost Comparison of Anti-TNF Agents in Rheumatoid Arthritis Patients Receiving Methotrexate for Plan and Group Managers"	
289	11/14/06		X	Software and document titled "Remicade Practice Management Assistant" [admitted as template not numbers]	
302	12/18/06		X	E-mail from Cheryl Cohen to Tom Weiss, et al. re "CIGNA & Aetna USHC Reimbursement Clarification"	
318	11/16/06		X	Email from Cathleen Dooley re: Follow-up of voice mail request	
330	1/19/07		X	Letter to All Orth Biotech Employees transmitting the Ortho Biotech "Best Practice Guidelines"	
331	12/18/06		X	Procrit Reimbursement Alternatives Presented by Documedics	
332	12/18/06		X	UJHCS Regional Managed Care Training	
334	11/16/06		X	Strategies for Shaping the Reimbursement Environment	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
339	11/16/06		X	Memorandum from C. Dooley to T. Amick re: Reimbursement Considerations for Spillover Planning	
343	12/18/06		X	Procrit Physician Office Strategy: Strategic Responses to Aranesp prepared by Charles River Associates	
344	12/8/06		X	Procrit Contracting: Modeling Provider Economics prepared by Charles River Associates	
346	11/16/06		X	Procrit Medicare Review prepared by Trinity Partners	
348	11/16/06		X	Document titled Ortho Biotech Historical List Price Change Procrit	
360	12/18/06		X	Memo from First Data Bank to Martha Hull re products included in databank	
364	12/18/06		X	Letter from Brock Weathers to Michael Kalson of Academy Orthopaedics attached	
365	11/16/06		X	Memorandum from M. Klein/ C. Dooley to S. Salmon	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
368	12/8/06		X	Maximum Value Programs for Preferred Physician Customers	
370	12/8/06		X	Procrit-CA-R 1.2CD-Rom: The Procrit vs. NESP Cost Analysis Presentation-R	
394	12/13/06		X	E-mail from David Maya re: Intron 95% AWP Reimbursement for Bladder	
395	1/19/07		X	Schering Intron Committed Member Program – Letter of Commitment	
397	12/13/06		X	Schering document titled “Cost Analysis for Superficial Bladder Cancer”	
408	11/16/06		X	Schering Laboratories Generic Strategy	
409	1/19/07		X	Proventil Inhaler Generics Strategies	
415	12/18/06		X	Warrick Memo from Darren K. Willoughby to Raman Kapur re: Updated Managed Care Pricing	
416	12/18/06		X	Integration of Warrick into Managed Care summary of review of mission	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				and action plan	
418	11/16/06		X	Schering Managed Care Memo from David Lee to Scott Larson re: GeriMed Warrick Contract Proposal	
421	12/18/06		X	Schering Laboratories Memo Harvey Weintraub to Richard Zahn re: Status Report – Warrick Pharmaceuticals	
422	1/19/07		X	Warrick Letter to Burt Orland Director of Pharmacy for Fallon re: contract price effective March 1, 1995 through December 31, 1995; and October 28, 1999 email from Patty Burke to Kathleen Flynn re: Fallon Clinic – Albuterol	
425	1/19/07		X	Letter from John F. Hoffman to L. Timothy Terry	
431	1/19/07		X	Warrick letter from Harvey J. Weintraub to Warrick Accounts re: Albuterol price increase	
432	12/18/06		X	Schering-Plough Memo from B. Michael Kennedy to Raman Kapur re: Rite-Aid Chargeback Program	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
433	1/19/07		X	Rite-Aid Corporation Secret Pricing	
434	12/18/06		X	Rite-Aid Pricing	
437	12/18/06		X	Warrick letter from Al Graf to John Ziebell re: Albuterol Price Increase	
438	12/18/06		X	Memo from Patty Hiley to Yvonne Cagnina re: Walgreen Company Credit, Line Rebate 1st Quarter 1996	
441	1/19/07		X	Warrick memo Al Graf to Raman Kapur re: Walgreen's Free Goods	
443	12/18/06		X	Letter Al Graf to John Ziebell re: Albuterol Price Change	
445	12/18/06		X	Letter Al Graf to John Ziebell re: Albuterol Sulfate Price Change	
453	1/19/07		X	Warrick Fax re: Total Line Rebate Program	
455	1/19/07		X	Warrick letter Jerome Sherman to Anthony Tavolaro re: Albuterol Sulfate Price Change	
456	12/18/06		X	Warrick letter to Anthony Tavolaro re: Total Line Rebate Program	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
461	12/18/06		X	Warrick Memo Jerome Sherman to Raman Kapur re: Rite Aid/CVS – Wholesaler Chargebacks	
466	1/19/07		X	Warrick letter to David Marshall re: Chargeback Rebate	
470	11/16/06 1/19/07		X limited	Schering-Plough Fax Richard Zahn to Raman Kapur re: Medco Proposal	
471	1/19/07		X	Schering/Warrick Albuterol Inhaler Action Plan, prepared by Steve Cooper and Mark Calabrese	
489	12/18/06		X	Email John Vanschaften to Mark Nolan, Kathleen Flynn, Serafina Oxner and Darren Ray re: Warrick Managed Price List – 1/01/00	
492	12/18/06		X	E-mail Debbie Kane to Greg Birch and others re: Price Alert!	
499	12/18/06		X	PowerPoint Slides re: Rebates	
503	1/19/07		X	Warrick Individual Prices and Promotion	
504	1/19/07		X	Warrick Trade Rebates – Generic	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				Division PowerPoint Presentation by Jackie Mobley	
505	12/18/06		X	Free Goods Summary	
523	1/19/07			Best Price, Medicaid Rebates and Nominal Pricing prepared by Michael Flinn	
573	12/18/06		X	Schering Plough Memorandum from Richard Zahn to Steve Andrzejewski, Joe Caso, Anne Fields, Bill Heiden, and Jim Mackey re: Product Pricing	
575	12/18/06		X	Spreadsheet Schering-Plough and Warrick Pharmaceuticals	
576	12/18/06		X	Agreement between Schering Corporation and TDI Managed Care Services, Inc.	
597	12/18/06		X	Agreement between Warrick and Bi-Coastal Pharmaceuticals re: employment as sales broker	
609	11/16/06		X	Generics – Generics Paper Managed Care by J. Audibeft (sp)	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
612	1/19/07		X	Warrick Account Information Forms re price change or rebate change to Albuterol Solution/Syrup	
619	12/18/06		X	Warrick Memos re Albuterol pricing	
636	12/18/06		X	Memo from Frank Musat to Gary Binder re Warrick Albuterol Pricing	
637	12/12/06		X	Memo from Harvey Weintraub to Mr. Zahn re Warrick pricing	
638	12/18/06		X	Documents between Warrick and Walgreens re Albuterol pricing and rebates 9/1/95 Letter from Al Graf to John Ziebell	
640	12/18/06		X	Addendum to 10/1/98 agreement between Schering Corporation and Scott & White Prescription Services	
641	12/18/06		X	Exhibit A to Addendum to 10/1/98 agreement between Schering Corporation and Scott & White Prescription Services	
642	12/18/06		X	Exhibit A-1 to Addendum to 10/1/98 agreement between Schering Corporation and Scott & White Prescription Services	
647	12/18/06		X	Memo from Patti Niehaus to Cheryl Burrell re PCA Health Plan of FL	
652	12/12/06		X	Memo from Richard Zahn to Raul Cesan re Generic Albuterol Solution/Syrup Introduction	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
689	12/18/06		X	Schering Laboratories Generic Market Strategic Plan	
702	12/18/06		X	Contract Admin. PPT.	
709	1/19/07		X	Schering-Plough Field Force of the Year 2000, a "how-to" manual	
710	12/18/06		X	Warrick letter Michael Kennedy to Linda Panke at Medical Economics Co. re: pricing and shipping info	
713	12/18/06		X	November 2001 Getting Away from AWP: Changing Medicare and Medicaid Drug Reimbursement	
714	11/16/06		X limited	Schering-Plough e-mail from Carolyn Kocis re: Nominal Pricing Meeting draft Executive Summary and Minutes	
718	12/18/06		X	Warrick memo Dave Reich to C. Hagman re: Price Change for Albuterol 20 mL	
719	12/12/06		X	Albuterol Price Notices	
720	12/18/06		X	Intron-A pricing and reimbursement	
721	12/18/06		X	E-mails re: Intron Reimbursement Issues- Summary and Calculation of Medicare Reimbursement- Example	
722	12/18/06		X	Intron-A Oncology 2003 Marketing Plan	
747	12/18/06		X	Memo from R.M. Loughlin to Attendees re Albuterol launch	
755	12/18/06		X	Memo from Harvey Weintraub to Richard Zahn re Warrick Albuterol-Retail Buying Groups	
771	12/12/06		X	Handwritten notes re Albuterol pricing	
772	12/12/06		X	Letter from Peter Kamins and Henry Weintraub to Michael LaBreque of	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				Jack Eckard Corp. re Proventil Chain Market Share Program	
773	12/18/06		X	Contract between Warrick and HealthPartners for Albuterol	
778	12/18/06		X	Memo from Harvey Weintraub to Distribution re HCFA – MAC Rulings	
779	12/12/06		X	Letter from Janet Miller of Medicap Pharmacies, Inc. to Jerry Sherman	
791	12/18/06		X	Memo from R. Kapur to D. Malanga, et al. re Price Reports to Third Parties; AWP, WAC, etc.	
809	12/18/06		X	Letter to Thomas Bliley from Richard Zahn	
820	12/18/06		X	Composite Exhibit of Price Increase Letters from Ron Krawczyk	
825	11/14/06		X	Remicade Price Increase History	
843	12/8/06		X	Email from Marsha Peterson to Doug Storer re: POA PowerPoint	
844	12/18/06		X	Smart Practices Require Best Practices from the OTN Website	
848	12/18/06		X	Email from Gena Cook to Marsha Peterson & Todd Little re: OHOA with Drug Purchases	
849	11/13/06		X	RedBook Product Listing Verification	
866	1/19/07		X	Administrative Services Account Agreement	
873	11/7/06		X	Analysis of CMS Average Wholesale Price Reform – Reimbursement for Part B Drugs	
899	12/18/06		X	2005 Hospital Contracting Plan, PFSW	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
953	1/19/07		X	Sheet Metal Workers' National Health Fund payment records for Paraplatin	
954	1/19/07		X	Sheet Metal Workers' National Health Fund payment records for Cytosan and Rubex	
955	1/19/07		X	Sheet Metal Workers' National Health Fund payment records for Procrit	
956	1/19/07		X	Sheet Metal Workers' National Health Fund payment records for Zoladex	
957	11/7/06		X	Sheet Metal Workers' National Health Fund payment records for Albuterol	
957A	11/7/06		X	Sheet Metal Workers' health insurance claim form for Albuterol (HCFA - 1500)	
976	11/16/06		X	Presentation: 1999 Rebate Recommendations	
978	12/18/06		X	Memo from Elaine Kling re "Urgent - Price Change Notification"	
979	11/16/06		X	Memo from C. Dooley to S. Welden re Medicare AWP Drug Reimbursement Proposal	
982D	12/4/06 def		X	Internal Memorandum from Michael Tilton re: Zoladex	
4000	11/7/06		X	Packet of Rebecca Hopkins' medical records	
4001	11/15/06		X	Written tutorial - Rosenthal	
4002	11/15/06		X	Slides from Rosenthal testimony	
4003	11/16/06		X	Letter: Shaughnessy to McShane 12/6/91	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
4004	11/16/06		X	Letter: Harberger to Engleman 9/26/95	
4006	11/28/06		X	1999 Operational Plan for the Prostate Cancer Portfolio Casodex and Zoladex	
4007	12/11/06		X	General Information on Track 1 Drugs	
4008	12/11/06		X	Alternative Thresholds per Court Discussion: Class 2	
4009	12/11/06		X	National Return to Practice Dollars	
4010	12/11/06		X	Incorporation of CMS ASP Methodology	
4011	12/11/06		X	Comparison to CMS ASPs	
4012	12/11/06		X	BCBS MA Payment Coverage for Non-Medigap Reimbursements; Sheet Metal Workers' National Health Fund Reimbursements; Pipefitters Reimbursement Coverage [admitted "with the limitation on multi-source." Trial Day 17 at 59:4-5]	
4015	12/6/06		X	Hearing on Reimbursement and Access to Prescription Drugs Under Medicare Part B before the Congressional Subcommittee on Health Care	
4016	12/8/06		X	Notice of Compliance Program Guidance for Pharmaceutical Manufacturers developed by the Office of the Inspector General, HHS	
4018	11/29/06		X	PriceWaterhouseCoopers Estimate of Savings to the Medicare Program 4/27/05 and 9/20/05 Update	
4019	11/29/06		X	MedPAC 7/13/06 Testimony before the Congressional	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				Subcommittee on Health	
4020	11/29/06		X	Testimony of Robert A. Vito 7/13/06 before the Congressional Subcommittee on Health	
4024	12/4/06		X	E-mail from Dean McAlister to various recipients re Provider Response: Tap Care and Cigna AZ	
4025	12/4/06		X	E-mail from Maureen Gillick to various recipients re: reimbursements for Zoladex vs. Lupron	
4027	12/6/06		X	Letter Donald Soltysiak to Jonathan Schechter, M.D. 2/13/92 re: prices for Bristol-Myers Oncology drugs	
4028	12/11/06		X	Replacement Pages for Hartman Direct Attachments (Attachments F.7, G.1.a, G.1.c, I.1, J.1.a and J.1.b)	
4029	12/11/06		X	Replacement Slides for Hartman Direct Testimony Presentation (slides 28, 35, 48, 54, 59, 96, 99,100, 104, 105, 106, 107 and 108)	
4030	12/11/06		X	Replacement Pages for Hartman Direct Report (pages 35, 36, 37,66 and 126)	
4032	12/11/06		X	Replacement Slide for Rosenthal Direct Testimony Presentation (slide 24 with notes)	
4033	12/11/06		X	Replacement Slides for Rosenthal Direct Testimony Presentation (slides 12, 13, 14, 15, 16, 17 and 24)	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
4034	12/11/06		X	Replacement Page for Rosenthal Direct Report (page 22)	
4040	1/4/07		X	Letter from Douglas Holtz-Eakin to Hon. William ("Bill") M. Thomas	
4043	12/8/06		X	Letter to Hon. Tom Bliley from Alan F. Holmer of PhRMA	
4044	12/8/06		X	Letter to Alan F. Holmer of PhRMA from Hon. Tom Bliley	
4047	12/8/06		X	Memorandum to Michael Pollock and Faheem from Marsha Peterson re Western Regional Summary – February	
4048	12/8/06		X	Email to multiple recipients from Craig M. Wilson re Dr. Giangreco	
4049	12/8/06		X	Plaintiffs' Shared Enterprises chart (corrected)	
4058	12/18/06		X	Report to the Congress: Effects of Medicare Payment Changes on Oncology Services	
4059	12/18/06		X	Statement of Frederick M. Schnell, M.D. before House Committee on Ways and Means	
4063	1/4/07		X	Monitoring Medicare Part B Drug Prices: A Comparison of Average Sales Prices to Average Manufacturer Prices	
4064	1/4/07		X	Comparison of Fourth Quarter 2005 Average Sales Prices to Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2006	
4065	1/4/07		X	Comparison of Fourth Quarter 2005 Average Sales Prices to Average Manufacturer Prices: Impact on	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
				Medicare Reimbursement for Second Quarter 2006	
4066	12/18/06		X	Remicade WAC Spread Analysis	
4069	12/18/06		X	Changes in Medicare Reimbursement for a Typical Administration of Zoladex	
4070	12/18/06		X	Changes in Medicare Reimbursement for a Typical Taxol Administration	
4071	12/18/06		X	Changes in Medicare Reimbursement for a Typical Remicade Administration	
4072	12/18/06		X	Changes in Medicare Reimbursement for a Typical Procrit Administration	
4073	1/4/07		X	Letter to Mark McClellan from Glenn M. Hackbarth, J.D.	
4074	1/4/07		X	Review of CMS's preliminary estimate of the physician update for 2005	
4075	12/12/06		X	First DataBank Monthly Interest 9/91	
4077	12/12/06		X	1991-2003 Red Books (partial)	
4078	12/13/06		X	Albuterol Sulfate price announcement	
4079	12/13/06		X	Memo to multiple recipients from Harvey Weintraub re Albuterol Solution 20ml Price Change	
4080	12/12/06		X	Letter to Jeanette Murphy from Harvey J. Weintraub	
4081	12/12/06		X	Letter to Warrick Accounts from Harvey J. Weintraub	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
4082	12/13/06		X	Letter to Warrick Accounts from Harvey J. Weintraub	
4083	12/12/06		X	Letter to Mr. Pat Byrnes from Al Graf	
4084	12/12/06		X	GPP Program New Product Proposal	
4086	12/12/06		X	Letter to Mr. Jacob Blatt from Harvey J. Weintraub	
4088	12/12/06		X	New Product Proposal	
4089	12/12/06		X	Memo re Price Increase	
4090	12/13/06		X	Email to multiple recipients from Aracelia Vila re Commitment to Care	
4091	1/4/07		X	Calculation of Volume-Weighted Average Sales Price for Medicare Part B Prescription Drugs	
4093	12/13/06		X	Email to multiple recipients from Todd Grisco re: 2001 CTC numbers	
4094	12/13/06		X	Email to multiple recipients from Todd Grisco re: 2001 CTC Free Drug	
4095	12/18/06		X	Changes in Medicare Reimbursement for a Typical Albuterol 0.083% Prescription	
4096	12/18/06		X	Number of Observations of Drug-Specific Average Spreads	
4097	12/18/06		X	Region A DMERC Supplier Manual 14.28 (Rev. 21, 03/02)	
4098	12/18/06		X	Region A DMERC Supplier Manual 14.28 (Rev. 13, 03/00)	
4099	12/18/06		X	Chart – HCPCS Modifiers	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
4100	12/18/06		X	Palmetto GBA - Fee Updates: Fourth Quarter 2001 Drug Fees	
4101	12/18/06		X	Palmetto GBA - 2002 Fourth Quarter Drug Fee Update	
4102	12/18/06		X	Palmetto GBA - 2003 Fourth Quarter Drug Fee Update	
4103	12/18/06		X	Palmetto GBA - Nebulizer Drugs - KP, KQ Modifiers and Units of Service	
4104	12/18/06		X	Palmetto GBA article - Nebulizer Drugs: Albuterol and Ipratropium	
4105	12/18/06		X	Sheet Metal Workers' health insurance claim form for Albuterol (HCFA - 1500)	
4106	12/18/06		X	Sheet Metal Workers payments for Albuterol Sulfate	
4107	12/18/06		X	Sheet Metal Workers Claims for Albuterol	
4109	1/19/07		X	Replacement Charts for Hartman Direct Attachments (Attachments G.4.a, G.4.b and G.4.c)	
4110	12/18/06		X	Replacement Charts for Hartman Direct Attachments (Attachments J.4.a and J.4.b)	
1099 def	1/4/07		X	Medicare Drug Reimbursements: A Broken System for Patients and Taxpayers, Joint Hearing before the Subcommittee on Health and the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, 107 th Cong. 89, First Session, Serial No. 107-65	

Pls' Ex.	Date Offered	Marked	Admitted	Description	Witness
1303 def	1/4/07		X	69 Fed. Reg. 66406, Table 41 Impact of Proposed Rule and Physician Fee Schedule Update on Medicare Payment for Selected Drug Administration Services Excluding the Effect of the 32 and 3% Transition Adjustments and Demonstration Project	